ARTUS CMV RGQ MDX KIT RECEIVES FDA APPROVAL

Qiagen’s Viral Burden Kit for CMV is Cleared by the FDA

Qiagen has received FDA approval for its artus CMV RGQ MDx kit. The kit is used to monitor Cytomegalovirus (CMV) viral burden in organ transplant patients. Due to the potential life-threatening conditions caused by the virus, as many as 60 percent of all transplant patients undergo repeated testing to determine CMV viral burden.

Qiagen’s kit is the only PCR-based assay optimized for low-to mid-throughput testing of CMV, to receive FDA approval. And, with a turn-around time of three hours, the assay returns faster results than other PMA approved tests. This can both save lives and reduce lab-associated costs